Integra LifeSciences Holdings Corporation (IART) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Integra LifeSciences Holdings Corporation (NASDAQ: IART) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $12.75 (-0.62% 1D, market cap $992.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IART ranks #991 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), IART carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 50.9%, and ROIC of -35.0%. By comparison, IRMD (iRadimed Corporation) holds a D+ grade (55/100 RQD, P/E 48.8x, ROIC 37.7%, cap $980.5M) and SIBN (SI-BONE Inc.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -10.3%, cap $951.5M). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).
Per IART's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000917520), Integra LifeSciences Holdings Corporation generated $1.64B in revenue (+1.5% YoY), -$516.8M in net income, and -$31.1M in free cash flow against $3.60B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 0.64 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 50.9% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While IART currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.68) and Max Pain ($13.39) forces dealer call-delta covering toward $21.51.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Integra LifeSciences Holdings Corporation (IART) slipped -0.62% to $12.75, trading at 34% of its 52-week range ($8.7 – $20.49). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Aurora® Surgiscope ® System Aurora® Surgiscope ® System PRINCETON, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced
UBS analyst Patrick Wood maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $19 to $14.
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable pr
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $15 to $13.
The updated analyst fair value estimate for Integra LifeSciences Holdings has shifted from US$18.38 to US$16.44, which points to a roughly 11% cut in where models now anchor the stock’s longer term potential. This reset
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $15 to $14.
BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $15 to $14.
Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target from $15 to $13.
Citizens analyst Daniel Stauder maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the price target from $25 to $22.
JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and lowers the price target from $17 to $14.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +1.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IART today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IART. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Integra LifeSciences Holdings Corporation (IART) ranks #991 by composite RQD confidence (19/100, grade E) and #357 by equity capitalization ($992.0M). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with IART at 19/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IART
ACTIVE
Integra LifeSciences Holdings Corporation | E | 19/100 | — | 50.9% | -35.0% | -0.62% | $992.0M | Benchmark Subject |
| IRMD iRadimed Corporation | D+ | 55/100 | 48.8x | 76.7% | 37.7% | -10.57% | $980.5M | /irmd-vs-iart → |
| SIBN SI-BONE Inc. | D+ | 52/100 | — | 79.6% | -10.3% | -5.27% | $951.5M | /sibn-vs-iart → |
| SGP SpyGlass Pharma Inc. | D- | 43/100 | — | — | -35.0% | -0.83% | $1.08B | /sgp-vs-iart → |
| BBNX Beta Bionics Inc. | D- | 36/100 | — | 55.4% | -22.1% | -4.72% | $910.6M | /bbnx-vs-iart → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Integra LifeSciences Holdings Corporation (IART) reported GAAP revenue of $1.64B (+1.5% vs. FY2024 revenue of $1.61B , and +6.1% cumulative change since FY2023) , GAAP net income of -$516.8M, operating cash flow of $50.4M, and free cash flow of -$31.1M (-224.4% YoY). On the balance sheet, IART closed FY2025 with $3.60B in total assets against $0 in total debt (Altman Z-Score: 0.64, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.64B | -$516.8M | $50.4M | -$31.1M | $3.60B | — |
| FY2024 (FY) | 2024-12-31 | $1.61B | -$6.9M | $129.4M | $25.0M | $4.04B | — |
| FY2023 (FY) | 2023-12-31 | $1.54B | $67.7M | $140.0M | $140.0M | — | — |
As of 2026-11-03, Integra LifeSciences Holdings Corporation (NASDAQ: IART) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $12.75 (-0.62% 1D, market cap $992.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IART ranks #991 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), IART carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 50.9%, and ROIC of -35.0%. By comparison, IRMD (iRadimed Corporation) holds a D+ grade (55/100 RQD, P/E 48.8x, ROIC 37.7%, cap $980.5M) and SIBN (SI-BONE Inc.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -10.3%, cap $951.5M). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).
Per IART's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000917520), Integra LifeSciences Holdings Corporation generated $1.64B in revenue (+1.5% YoY), -$516.8M in net income, and -$31.1M in free cash flow against $3.60B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
IART last traded at $12.75 (-0.62% on volume of 1,038,790 shares), positioning the stock -13.15% below its 50-day simple moving average ($14.68) and -9.38% below its 200-day simple moving average ($14.07). Across its 52-week range of $8.70 to $20.49, IART sits at the 34.4% percentile with a 14-day RSI of 43.0 (NEUTRAL RANGE) and an implied next-earnings move of ±10.6% ($11.40 to $14.10).
Why IART Stock slipped -0.62% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, IART carries an RQD Score of 20 out of 100, a letter grade of E, and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 3/20 (ROIC of -35%; FCF yield of -3.11%), indicating that the business is not currently generating economic returns on invested capital or free cash flow relative to its market value. Whale 13F Flow scores 5/20, reflecting institutional accumulation and options positioning that the source characterizes as weak. Insider Conviction scores 3/20 based on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 3/20 with a Beta of 1.0 and sector sensitivity noted. Forensic Balance Sheet scores 6/20, anchored by an Altman Z of 0.64 (a distress-zone reading), a Piotroski F of 4/9, and a Debt/Equity of 0.5. For a prospective investor, the practical implication is that the stock's current price of 12.83 is not supported by the cash-generation, ownership-signal, or balance-sheet metrics in the source data. Any upside case would depend on a reversal in operating performance that the present data does not evidence, and the rating's low scores across four of five pillars point to a high-risk profile for evaluating the stock today.
Per the Profile, Integra LifeSciences Holdings Corporation (IART) is a NASDAQ-listed issuer in the Health Care sector and the Medical/Dental Instruments industry. The source data does not provide a description of specific products, customers, or revenue-generation mechanics beyond the sector and industry classification and the reported financials. Per the Snapshot market data, the company reports a gross margin of 50.9%.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $1635.2M | $-493.4M | $-516.8M | N/A | $-31.1M | $235.0M | N/A |
| FY 2024 | $1610.5M | $28.4M | $-6.9M | N/A | $25.0M | $246.4M | N/A |
| FY 2023 | $1541.6M | $111.5M | $67.7M | N/A | $140.0M | N/A | N/A |
Per the SEC financials, revenue rose from $1541.6M in FY 2023 to $1635.2M in FY 2025, while operating income moved from $111.5M to $-493.4M over the same span, and net income moved from $67.7M to $-516.8M. Per the Snapshot market data, the operating margin is -30.2% and the net margin is -31.6%, with ROIC at -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.64 and the Piotroski F-Score is 4/9, with Debt/Equity at 0.5. Cash was $235.0M at FY 2025 versus $246.4M at FY 2024.
Per the Butterfly Supply-Chain Graph, the supply chain is marked NONE, with no butterfly links and no proprietary signals recorded. Sector is Health Care and industry is Medical/Dental Instruments. No upstream or downstream dependencies, sector correlations, or 2nd-order bottlenecks are identified in the source data.
Real-time company headlines, analyst actions, and sector developments for Integra LifeSciences Holdings Corporation (IART) • Click "Debate This Headline" to argue it in the Roar Pit below
Aurora® Surgiscope ® System Aurora® Surgiscope ® System PRINCETON, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced
UBS analyst Patrick Wood maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $19 to $14.
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable pr
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $15 to $13.
The updated analyst fair value estimate for Integra LifeSciences Holdings has shifted from US$18.38 to US$16.44, which points to a roughly 11% cut in where models now anchor the stock’s longer term potential. This reset
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $15 to $14.
BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $15 to $14.
Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target from $15 to $13.
Welcome to the IART (Integra LifeSciences Holdings Corporation) Roar Pit. Current RQD Composite is 20/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on IART, but look at what you are paying: current EV/EBITDA multiples with 50.9% gross margins. Unless Integra LifeSciences Holdings Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on IART, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $12.83 (52-wk range $8.70 - $20.49), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).